Bio Drawdown In Historic Range
Insights - “Buy when there’s blood in the streets, even if the blood is your own.” – Nathan Rothschild (banker)“Be greedy when others are fearful.” – Warren … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Initial Omicron Data Out of South Africa Not A Cause For Alarm
Insights - The latest COVID variant Omicron has been detected in at least 5 US states, with more expected. Worldwide headlines of this variant have caused uncertainty … Continue Reading
Premium
Affimed Continues Promising Data With NK Cell Combo
Insights - Affimed reported surprise data this morning for AFM13+NK cells with partner MD Anderson. This is the data that was expected in mid-December, which now the company will … Continue Reading
Premium
Eloxx Cagey With Phase 2 Mono Cystic Fibrosis Data
Insights - Eloxx (ELOX) shared monotherapy data from their Phase 2 in cystic fibrosis this morning. The data that was reported was not bad, but it left investors wanting … Continue Reading
Premium
Expectations for MDNA11 Biomarker Data
Insights - Medicenna (MDNA) reported a business update late last week. Biomarker data continues to be on schedule for end of year 2021 and initial efficacy data … Continue Reading
PremiumEloxx Sees Slight Delay In Combo CF Data, Mono Still Out Q4 2021
Insights - Eloxx (ELOX) reported Q3 business update last week which caused the stock to trade lower, presumably because combination data was pushed back from Q1 2022 … Continue Reading
PremiumMore AFM13+NK MD Anderson Data Likely in Mid-December
Insights - Affimed (AFMD) announced a few updates this morning with ASH nearing. Overall, little substance was shared, which was disappointing as we were expecting AFM13+NK data … Continue Reading
Premium